Cat. No.: HY-124958

NDMC101

Customer Review

Based on 1 Customer Validation

NDMC101 is a potent osteoclastogenesis inhibitor and inhibits osteoclast differentiation via down-regulation of NFATc1-modulated gene expression. NDMC101 is similar to the DPP4 substrate and is a significant inhibitor of early T-cell activation via DPP4 inhibition. NDMC101can be used for study of bone disorders, such as rheumatoid arthritis, and synovial inflammation et al.

For research use only. We do not sell to patients.

Purity: 99.91%
CAS No.: 1308631-40-4
Formula: C₁₃H₉ClFNO₂
Molecular Weight:265.67

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

NDMC101 Chemical Structure

CAS No.: 1308631-40-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

DPP-4

All NF-κB Isoforms :

All Dipeptidyl Peptidase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
RAW264.7	CC₅₀	23.2 μM Compound: 1a, NDMC101	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in survival rate after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in survival rate after 24 hrs by MTT assay	[PMID: 25200306]
RAW264.7	IC₅₀	>10 μM Compound: NDMC101	Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as decrease in TRAP-positive multinucleated cells after 4 days by TRAP staining Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as decrease in TRAP-positive multinucleated cells after 4 days by TRAP staining	[PMID: 26005025]
RAW264.7	IC₅₀	10 μM Compound: 1a	Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells assessed as reduction in TRAP-positive multinucleated cells level incubated with compound in presence of RANKL for 4 days by TRAP staining based light microscopic analysis rela Inhibition of RANKL-induced osteoclast differentiation in mouse RAW264.7 cells assessed as reduction in TRAP-positive multinucleated cells level incubated with compound in presence of RANKL for 4 days by TRAP staining based light microscopic analysis rela	[PMID: 27089213]
RAW264.7	IC₅₀	10 μM Compound: 1a, NDMC101	Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as TRAP+ multinucleated cells level incubated for 4 days by TRAP staining assay Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as TRAP+ multinucleated cells level incubated for 4 days by TRAP staining assay	[PMID: 25200306]
RAW264.7	IC₅₀	12.5 μM Compound: 1a, NDMC101	Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as reduction in TRAP activity incubated for 4 days by TRAP staining assay Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as reduction in TRAP activity incubated for 4 days by TRAP staining assay	[PMID: 25200306]
RAW264.7	IC₅₀	15 μM Compound: NDMC101	Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells	[PMID: 26005025]

In Vitro

NDMC101 (10-15 μM) inhibits RANKL-induced osteoclast differentiation of bone marrow-derived macrophages (BMDMs) and RAW 264.7 cells^[1].
NDMC101 (15 μM) decreases RANKL-induced expression of the osteoclastogenic genes?Nfatc1,?Acp5,?Ctsk,?Oscar,?Itgb3, and?Dcstamp?in BMDMs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1308631-40-4
Appearance Solid
Molecular Weight 265.67
Formula C₁₃H₉ClFNO₂
Color White to off-white
SMILES

OC1=C(C=CC=C1)C(NC2=CC=C(C=C2F)Cl)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (376.41 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.7641 mL

18.8203 mL

37.6407 mL

5 mM

0.7528 mL

3.7641 mL

7.5281 mL

10 mM

0.3764 mL

1.8820 mL

3.7641 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Chia-Pi Cheng, et al. A benzamide-linked small molecule NDMC101 inhibits NFATc1 and NF-κB activity: a potential osteoclastogenesis inhibitor for experimental arthritis. J Clin Immunol. 2012 Aug;32(4):762-77. [Content Brief]

[2]. Jun-Ting Liou, et al. A salicylate-based small molecule HS-Cm exhibits immunomodulatory effects and inhibits dipeptidyl peptidase-IV activity in human T cells. Eur J Pharmacol. 2014 Mar 5;726:124-32. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.7641 mL	18.8203 mL	37.6407 mL	94.1017 mL
	5 mM	0.7528 mL	3.7641 mL	7.5281 mL	18.8203 mL
	10 mM	0.3764 mL	1.8820 mL	3.7641 mL	9.4102 mL
	15 mM	0.2509 mL	1.2547 mL	2.5094 mL	6.2734 mL
	20 mM	0.1882 mL	0.9410 mL	1.8820 mL	4.7051 mL
	25 mM	0.1506 mL	0.7528 mL	1.5056 mL	3.7641 mL
	30 mM	0.1255 mL	0.6273 mL	1.2547 mL	3.1367 mL
	40 mM	0.0941 mL	0.4705 mL	0.9410 mL	2.3525 mL
	50 mM	0.0753 mL	0.3764 mL	0.7528 mL	1.8820 mL
	60 mM	0.0627 mL	0.3137 mL	0.6273 mL	1.5684 mL
	80 mM	0.0471 mL	0.2353 mL	0.4705 mL	1.1763 mL
	100 mM	0.0376 mL	0.1882 mL	0.3764 mL	0.9410 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

NDMC101

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Pyroptosis Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Protease Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Amino Acid Metabolism Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Lactylation Compound Library

All NF-κB Isoforms

All Dipeptidyl Peptidase Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

NDMC101 Related Classifications

Cat. No.: HY-124958